Two-Case Report Evaluates Lisaftoclax Plus Ixazomib and Dexamethasone in Relapsed Multiple Myeloma
Report reveals disease control in two high-risk myeloma patients
This publication is a case report involving 2 patients with transplant-ineligible relapsed or refractory ultra-high-risk multiple myeloma. I…
Two patients with ultra-high-risk myeloma achieved durable disease control using a new drug combination after CAR-T therapy.
Qualitative review of tocilizumab use with bispecific antibodies in relapsed/refractory multiple myeloma
New drugs for myeloma need a safety net to work well
This qualitative interview review synthesizes perspectives from ten hematologists/oncologists regarding bispecific antibody (BsAb) use in re…
New powerful drugs treat myeloma better, but patients need a safety net to handle side effects and stay on track for a long time.
Narrative review on gamma delta T cell therapies for hematologic malignancies and immune cytopenias
New T-Cells Fight Blood Cancer Without Matching Your DNA
This narrative review synthesizes evidence on gamma delta T cell therapies for acute leukemias, lymphomas, multiple myeloma, and immune cyto…
A new type of immune cell could finally treat blood cancers that other therapies cannot touch.
Systematic review of MS proteomics/metabolomics in multiple myeloma cohorts
New Blood Test Spots Myeloma Return Months Earlier
This systematic review synthesizes evidence from 19 studies involving 1,077 screened records regarding quantitative mass spectrometry-based …
This new test could give patients and doctors a critical head start in fighting a return of multiple myeloma.
Case Report Describes Non-Secretory Multiple Myeloma With Eosinophilia in a 56-Year-Old Man
Back Pain and High White Cells: A Hidden Cancer Case
This case report details a 56-year-old man presenting with multiple myeloma and eosinophilia. Diagnosis of non-secretory multiple myeloma wa…
This case shows how a rare blood cancer can hide behind common symptoms, making early diagnosis difficult but crucial.
Review Article Examines Bisphosphonates and Denosumab for Multiple Myeloma Associated Bone Disease
Bone Pain in Cancer: New Options, Real Risks
This review article examines the use of bisphosphonates and denosumab in patients with multiple myeloma. The authors synthesize current know…
New drugs target bone breakdown in multiple myeloma without kidney damage, offering hope for patients with weak bones and severe pain.
BCMA CAR-T therapy achieves 100% MRD negativity in transplant-ineligible multiple myeloma patients.
A One-Time Treatment Erases Early-Stage Blood Cancer in Older Adults
This Phase II, open-label, single-arm trial evaluated BCMA CAR-T infusion in 36 patients with newly diagnosed multiple myeloma ineligible fo…
A new approach using a patient’s own re-engineered immune cells is showing unprecedented success in wiping out a common blood cancer from th…
Anti-BCMA CAR T-cell therapy bb21217 with bb007 showed 69.4% response in relapsed multiple myeloma.
Memory Cells Make CAR T Last Longer
This Phase I study evaluated anti-B-cell maturation antigen CAR T-cell therapy bb21217 manufactured with the phosphoinositide 3-kinase inhib…
CAR T cells trained to act like long-term guards may keep multiple myeloma away for years instead of burning out quickly after initial treat…
Carfilzomib-lenalidomide-dexamethasone improves progression-free survival versus lenalidomide after transplant in multiple myeloma
Adding carfilzomib to lenalidomide improved survival in multiple myeloma patients after stem cell transplant
In a phase 3 trial of 180 patients with newly diagnosed multiple myeloma after autologous HSCT, carfilzomib-lenalidomide-dexamethasone maint…
Adding carfilzomib to lenalidomide after stem cell transplant boosted four-year survival to 67.5% compared to 38.0% for patients on lenalido…
Multiple myeloma diagnosis associated with markedly increased hematologic second primary malignancies in 279,894 patients.
Multiple myeloma patients show higher risk of second blood cancers, review finds
This systematic review and meta-analysis evaluated second primary malignancy risks in 279,894 patients with multiple myeloma compared to the…
Multiple myeloma patients face a threefold higher risk of developing a second blood cancer compared to the general population, according to …
Systematic review explores necroptosis as a therapeutic target in multiple myeloma
Could a different kind of cell death help treat stubborn blood cancer?
A systematic review integrates current evidence on necroptosis in multiple myeloma. It reports that necroptosis-associated genes influence p…
When standard treatments fail, triggering a different cell death process called necroptosis might kill resistant cancer cells and boost the …
CellSearch CMMC assay shows analytical sensitivity for non-invasive MRD monitoring in multiple myeloma
Could a simple blood test replace painful bone marrow biopsies for myeloma monitoring?
A study of unspecified design evaluated the analytical performance of the CellSearch CMMC assay for minimal residual disease monitoring in m…
A new blood test can detect single cancer cells left after multiple myeloma treatment, offering a less invasive way to monitor disease level…